List of Excipients in Branded Drug ALTABAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	ALTABAX	retapamulin	16110-518	PETROLATUM	2027-02-14
Rebel Distributors Corp	ALTABAX	retapamulin	21695-644	PETROLATUM	2027-02-14
Physicians Total Care Inc	ALTABAX	retapamulin	54868-6096	PETROLATUM	2027-02-14

Altabax Excipient Strategy and Commercial Opportunities for Retapamulin Ointment

Last updated: August 9, 2026

Altabax is a topical retapamulin 1% ointment approved by the U.S. Food and Drug Administration for impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes in patients aged nine months and older. Its excipient platform is deliberately simple: white petrolatum is the listed inactive ingredient, creating an anhydrous, occlusive ointment base without an aqueous preservative system.[1]

The commercial opportunity is not primarily a novel excipient claim around retapamulin. It is the development of differentiated generic, private-label, pediatric, and next-generation topical products that improve usability, packaging, washability, and adherence while preserving retapamulin exposure and microbiological performance.

What excipients are used in Altabax?

Altabax uses white petrolatum as its listed inactive ingredient. The formulation is an oil-based ointment rather than a cream, gel, lotion, or aqueous emulsion.[1]

Product attribute	Altabax profile
Active ingredient	Retapamulin
Strength	1% w/w
Dosage form	Topical ointment
Listed inactive ingredient	White petrolatum
Indication	Impetigo
Patient population	Adults and pediatric patients aged 9 months and older
Administration	Thin layer applied twice daily for five days
Application area	Up to 2% of total body surface area
Primary formulation function	Occlusive delivery and skin protection
Preservative system	No separate aqueous preservative system is listed

White petrolatum supplies several formulation functions. It reduces transepidermal water loss, remains on the skin after application, provides lubrication, and supports a low-water-activity environment. The excipient also minimizes the number of formulation variables that can affect retapamulin stability.

The formulation has commercial advantages in manufacturing and regulatory comparability. A single-excipient base reduces the number of inactive ingredients that a generic sponsor must match or justify. It also reduces risks associated with preservative irritation, emulsion instability, pH drift, and microbial contamination.

Why was white petrolatum selected for retapamulin?

White petrolatum is well suited to a topical antibiotic intended for short-duration treatment of localized bacterial skin infection. Its principal value is physical rather than pharmacologically active.

Occlusion and residence time

An occlusive petrolatum layer can increase hydration of the stratum corneum and extend contact between retapamulin and the affected skin surface. Longer residence time can support twice-daily dosing and reduce the need for frequent reapplication.

Low formulation complexity

Anhydrous petrolatum avoids several problems associated with water-containing systems:

• No aqueous phase requiring preservation
• Lower microbial growth risk during storage
• No emulsion phase separation
• No pH-dependent stability program
• Fewer excipient compatibility variables
• Simpler scale-up and filling operations

Pediatric tolerability

Altabax is approved for children nine months and older. A petrolatum-only base avoids alcohol, fragrance, and several common preservatives that can cause stinging or sensitization. This supports pediatric positioning, although petrolatum can feel greasy and may stain clothing.

Limitations of the base

The same properties create market openings. Petrolatum ointments may have poor cosmetic acceptability, limited washability, weak patient preference, and difficult application from rigid tubes. These issues matter in pediatric care, where caregivers control administration and treatment completion.

What formulation patents protect Altabax?

The commercial protection for Altabax historically centered on retapamulin and its antibacterial use rather than a complex excipient platform. The marketed dosage form uses a conventional petrolatum base, and the FDA label does not identify a proprietary multi-excipient delivery system.[1]

Potentially relevant intellectual-property categories include:

IP category	Relevance to Altabax
Retapamulin compound patents	Protect the active pharmaceutical ingredient and related pleuromutilin chemistry
Antibacterial method-of-use patents	May cover treatment of impetigo or susceptible bacterial skin infections
Topical formulation patents	May cover specific retapamulin compositions, concentration ranges, or delivery systems
Manufacturing patents	May cover synthesis, purification, polymorph control, or processing
Packaging and device patents	May cover tubes, pumps, applicators, or unit-dose delivery
Trademark rights	Protect the Altabax brand, not the active ingredient

A commercial entrant should separate active-ingredient patent risk from formulation risk. A simple petrolatum-based generic may face a different patent profile from a cream, foam, hydrogel, spray, or enhanced-delivery product.

The Orange Book remains the controlling source for FDA-listed patents, regulatory exclusivity, and reference-product information. Patent status must be reviewed by jurisdiction and patent family because U.S. Orange Book listings do not determine protection in Europe, Canada, Japan, or emerging markets.[2]

When did Altabax lose exclusivity?

Altabax received FDA approval in 2007.[3] The five-year new chemical entity exclusivity period associated with the original approval would have expired in 2012, subject to the precise regulatory classification and any applicable pediatric extension. Any later market protection would depend on listed patents, pediatric exclusivity, litigation outcomes, and product-specific regulatory records.

The practical commercial question is whether enforceable patent claims remain relevant to a proposed retapamulin product. The answer depends on the proposed product:

• A conventional 1% petrolatum ointment presents the highest risk of overlapping formulation claims.
• A cream or gel may avoid some ointment claims but could create new formulation patents.
• A different strength or delivery system could require a separate FDA regulatory strategy.
• A product using the same active ingredient for a different indication may encounter method-of-use claims.

FDA generic approval does not itself establish freedom to operate. A sponsor must assess Orange Book listings, patent-family expiration dates, terminal disclaimers, reexamination or post-grant proceedings, and litigation history before launch.

What is the Orange Book status of Altabax?

The Orange Book identifies the reference listed drug and any FDA-recognized patents or exclusivity information associated with the product.[2] The regulatory pathway for a conventional generic would generally be an abbreviated new drug application if the proposed product can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for a topical product.

For topical semisolid products, the regulatory burden may include:

• Same active ingredient, dosage form, strength, and route
• Comparable qualitative and quantitative composition, subject to FDA requirements
• Comparative physicochemical characterization
• In vitro release testing
• In vitro permeation testing where applicable
• Drug-product performance testing
• Microbiological quality testing
• Container-closure compatibility
• Demonstration that the formulation does not alter safety or effectiveness

The FDA has issued product-specific guidance for certain topical products and may require a tailored approach for retapamulin. A sponsor cannot assume that a simple qualitative match to white petrolatum eliminates all performance testing.

What generic entry risks exist for Altabax?

The principal generic risks are regulatory equivalence, patent timing, market size, and commercial substitution.

Regulatory risk

A petrolatum-based ointment may be straightforward to manufacture, but the sponsor still must demonstrate consistent retapamulin distribution, content uniformity, viscosity, spreadability, particle-size control if relevant, and release performance.

Patent risk

Paragraph IV certification may be required if an ANDA applicant believes an Orange Book-listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor may file infringement litigation within the statutory period, triggering a 30-month stay of approval in many circumstances under the Hatch-Waxman framework.[4]

A first applicant with a successful Paragraph IV strategy could obtain 180-day generic exclusivity if statutory conditions are satisfied. That opportunity is more valuable when the reference product has meaningful prescription volume and limited therapeutic substitution.

Market risk

Impetigo is often treated for only five days. The short course limits annual volume per patient and reduces the value of premium packaging unless the product achieves strong payer coverage or institutional adoption.

Substitution risk

Retapamulin competes with lower-cost topical antibiotics, particularly mupirocin, as well as antiseptic treatment, hygiene measures, and systemic antibiotics for selected patients. The commercial case for a generic depends on price, formulary status, distributor access, and prescriber preference rather than clinical differentiation alone.

What excipient strategies could improve Altabax?

A successor product can target usability without changing the active molecule.

Petrolatum optimization

A sponsor could use pharmaceutical-grade petrolatum with controlled rheology, improved spreadability, lower odor, and more consistent texture. These changes may improve patient acceptance while maintaining the basic ointment concept.

The main risk is that changes in petrolatum source, grade, or processing can alter retapamulin release and skin deposition. Any excipient change must be evaluated against the reference product.

Absorption-base systems

An absorption ointment or water-in-oil system could improve spreadability and reduce the heavy feel of pure petrolatum. Candidate excipients may include carefully selected emulsifiers, mineral oils, waxes, or medium-chain lipids.

These systems introduce new risks:

• Preservative requirements if water is present
• Emulsion instability
• Increased irritation potential
• Greater manufacturing complexity
• New extractables and leachables concerns
• More difficult bioequivalence justification

Washable creams

A cream could appeal to caregivers who dislike greasy ointments. The commercial positioning would be improved cosmetic acceptability and easier removal from skin and clothing.

A cream is not automatically interchangeable with the reference ointment. The change in vehicle can alter retapamulin thermodynamic activity, partitioning, skin penetration, drying time, and microbial performance.

Hydrogels and polymeric systems

A hydrogel or polymer-based system could provide a non-greasy profile and controlled spreading. However, a water-containing gel would require preservation and tighter control of pH, viscosity, microbial limits, and active stability.

Film-forming systems

A film-forming spray or solution could reduce transfer to clothing and improve dosing convenience. This approach creates substantial technical and regulatory risk because solvents, film-formers, and drying behavior can affect irritation and exposure.

What packaging opportunities exist for retapamulin?

Packaging may offer a lower-risk differentiation path than reformulation.

Packaging concept	Commercial benefit	Main risk
Small unit-dose sachets	Pediatric convenience and hygiene	Higher packaging cost
Metered-dose pump	Dose consistency and reduced tube contamination	Device combination-product complexity
Narrow-tip applicator	Better localized application	Clogging and dose variability
Multi-dose airless pump	Reduced exposure to air and handling	Higher manufacturing cost
Child-resistant tube	Household safety	Reduced ease of use
Institutional pack	Clinic and urgent-care efficiency	Limited retail appeal

Unit-dose packaging could support urgent-care, pediatric, and institutional channels. The drawback is cost. For a low-volume, short-course antibiotic, packaging economics may outweigh the adherence benefit unless the product is sold through premium channels.

Which companies are challenging Altabax?

The competitive field includes manufacturers of generic topical antibiotics, branded dermatology products, and alternative anti-infective products. The most direct commercial comparator is mupirocin, which has broad generic availability and strong physician familiarity.

Retapamulin has a narrower indication and a higher potential price position than generic mupirocin. A retapamulin generic would compete on formulary economics and tolerability, while a reformulated product would need a clear advantage in application, adherence, or skin feel.

No biosimilar pathway applies. Retapamulin is a small-molecule antibacterial, not a biologic. Competitive risk therefore comes from conventional generics and therapeutic alternatives, not biosimilar substitution.

How strong is the Altabax patent estate?

The excipient-related patent position appears structurally less defensible than an estate built around a proprietary delivery technology. White petrolatum is a longstanding compendial excipient, and the label identifies no complex excipient architecture.[1]

Patent strength is likely to depend on:

1. Whether live claims cover retapamulin itself.
2. Whether claims cover the 1% topical ointment specifically.
3. Whether method-of-use claims remain enforceable.
4. Whether manufacturing claims create a practical barrier.
5. Whether a competing product can design around the claimed vehicle.
6. Whether the commercial market supports litigation.

A plain generic ointment may be technically easy to reproduce but legally exposed if active-ingredient or use claims remain enforceable. A differentiated cream or device may reduce infringement risk but increase regulatory cost.

What commercial opportunities exist for Altabax excipients?

The highest-probability opportunities are:

• A low-cost generic 1% ointment using a closely comparable petrolatum base.
• A private-label pediatric ointment for retail and urgent-care channels.
• Unit-dose packaging for clinics, emergency departments, and pediatric practices.
• A cosmetically improved ointment with better spreadability and reduced greasiness.
• A washable cream or water-in-oil system positioned for caregiver preference.
• Regional licensing of retapamulin formulation, manufacturing, or distribution rights.
• Contract manufacturing of anhydrous retapamulin ointment for markets where branded supply is limited.

The strongest near-term strategy is usually a reference-matched petrolatum product combined with differentiated packaging. A reformulated cream may offer greater commercial upside, but it carries materially higher development, equivalence, patent, and manufacturing risk.

Key Takeaways

• Altabax contains retapamulin 1% in a white petrolatum ointment base.
• The excipient strategy is simple, anhydrous, occlusive, and compatible with pediatric topical use.
• White petrolatum reduces formulation and preservation complexity but creates greasiness and poor washability.
• The main generic opportunity is a reference-matched ointment, while the main branded opportunity is improved usability.
• Packaging, dosing convenience, and caregiver acceptability may offer safer differentiation than major vehicle changes.
• No biosimilar risk applies because retapamulin is a small-molecule drug.
• Paragraph IV strategy depends on the current Orange Book listing and the live status of relevant retapamulin, formulation, method-of-use, and manufacturing patents.
• Mupirocin is the principal commercial benchmark because of its broad generic availability and established prescribing base.

FAQs

Can retapamulin be formulated without white petrolatum?

Yes. Retapamulin could be developed in a cream, gel, emulsion, or alternative ointment base, but the new vehicle would require comparative formulation and performance testing and could create a separate patent position.

Is white petrolatum a preservative?

No. White petrolatum is an occlusive hydrocarbon base, not a conventional antimicrobial preservative. Its anhydrous nature reduces the formulation’s susceptibility to microbial growth.

Would a retapamulin cream be automatically substitutable for Altabax ointment?

No. A cream and an ointment are different dosage forms from a formulation and regulatory perspective. Substitution depends on FDA approval, product labeling, pharmacy rules, and demonstrated equivalence.

Can a company sell a retapamulin product in a different tube without changing the formulation?

Potentially. Packaging changes can be pursued independently, but the sponsor must assess dose delivery, container-closure integrity, compatibility, extractables and leachables, and stability.

Is retapamulin suitable for a combination product with a corticosteroid?

A retapamulin-corticosteroid combination would be a new product with a separate clinical and regulatory rationale. It could create a differentiated indication but would also raise safety, efficacy, dosing, and combination-drug patent issues.

References

1. U.S. Food and Drug Administration. (2019). Altabax (retapamulin) ointment, 1%: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2007). Altabax approval letter and regulatory review materials.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Act.